Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes
NCT03314246 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 111
Last updated 2020-02-28
Summary
Background: Ramadan fasting is a religious observance carried out by Muslims all over the world. During Ramadan, Muslims abstain from eating, drinking, and smoking during daylight hours. Although Muslims who are ill, including patients with diabetes, are exempted from fasting, many devoted Muslim patients still insist on fasting despite being advised not to by their healthcare providers. Concerns have been raised over how the practice of fasting may affect the metabolic control of Muslim patients with diabetes. Furthermore, it has also been postulated that the act of fasting may increase the risk of hypoglycemia or glucose toxicity. Although practice algorithms and suggestions on the use of glycemic therapies during fasting have been discussed internationally. they are not generalizable as the observances of Ramadan, duration of fasting and the food ingested differ from one country to another.
Aims: This study aims to develop and implement a clinical practice dose-adjustment algorithm dedicated to the care of Singaporean patients with diabetes who fast during Ramadan.
Hypothesis: The use of clinical practice dose-adjustment algorithm can improve both clinical and humanistic outcomes of patients with type 2 diabetes who wish to fast during Ramadan.
Methods: This is a prospective, randomized, interventional study involving patients with type 2 diabetes who wish to fast for at least 10 days during Ramadan. Eligible patient attending a primary care institution or an outpatient specialist clinic of a tertiary institution will be approached to participate in the study. Consented patients will be randomized to either intervention arm or control arm. Patients in the control arm will receive usual care while patients in the intervention arm will be given additional education session on Ramadan fasting related diabetic management advice and an algorithm that was developed by the study team members based on international guidelines, to guide them on self-management during Ramadan. The primary outcomes will be change in HbA1c. Secondary outcomes include change in fasting blood glucose, post prandial blood glucose, medication adherence and humanistic outcomes. The safety outcomes include self reported incidence of major and minor hypoglycemia as well as hyperglycemia during Ramadan month. All outcomes will be measured at baseline, during Ramadan and at 3 month post Ramadan.
Significance: The validation of the algorithm through this study will ensure effective and safe fasting of patients with type 2 diabetes during Ramadan.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- OTHER
-
FAST
Fasting Algorithm for Singaporeans with Type 2 Diabetes
- OTHER
-
Standard of care
Standard of care
Sponsors & Collaborators
-
National University of Singapore
collaborator OTHER -
Tan Tock Seng Hospital
collaborator OTHER -
National Healthcare Group, Singapore
collaborator OTHER_GOV -
Joyce Lee
lead OTHER
Principal Investigators
-
Lee, Pharm D · National University of Singapore
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-03
- Primary Completion
- 2019-02-06
- Completion
- 2019-02-06
Countries
- Singapore
Study Locations
More Related Trials
-
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore
NCT02578563 ·Status: COMPLETED
-
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
NCT02946632 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
NCT05914857 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
NCT02964572 ·Status: COMPLETED ·Phase: NA
-
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
NCT00744926 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
NCT04219124 ·Status: COMPLETED ·Phase: PHASE4
-
The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients
NCT05611684 ·Status: RECRUITING ·Phase: PHASE4
-
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
NCT05029115 ·Status: ENROLLING_BY_INVITATION
-
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy
NCT01871428 ·Status: COMPLETED ·Phase: PHASE3
-
A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea
NCT04980014 ·Status: COMPLETED
-
A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes
NCT01117103 ·Status: COMPLETED
-
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01294423 ·Status: COMPLETED ·Phase: PHASE3
-
SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
NCT02696941 ·Status: COMPLETED ·Phase: PHASE1
-
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
NCT02284269 ·Status: UNKNOWN
-
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes
NCT01176097 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin
NCT03631134 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
NCT01018173 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
NCT01456195 ·Status: COMPLETED ·Phase: PHASE3
-
A Real World Experience of Dapagliflozin in Type 2 Diabetes
NCT02966626 ·Status: COMPLETED
-
Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients
NCT00972244 ·Status: COMPLETED ·Phase: PHASE2
-
Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)
NCT00301392 ·Status: COMPLETED ·Phase: PHASE4
-
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
NCT01524705 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
NCT00763022 ·Status: COMPLETED ·Phase: PHASE3
-
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796 ·Status: COMPLETED ·Phase: PHASE2
-
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
NCT02887625 ·Status: UNKNOWN ·Phase: NA